keyword
MENU ▼
Read by QxMD icon Read
search

Follicular lymphoma

keyword
https://www.readbyqxmd.com/read/28340875/angioimmunoblastic-t-cell-lymphoma
#1
REVIEW
Alessandro Broccoli, Pier Luigi Zinzani
Angioimmunoblastic T-cell lymphoma is a follicular T-helper-derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. The outcomes reported with anthracycline-containing regimens are poor; therefore autologous transplantation in first remission should be offered whenever possible. Newer approaches are urgently needed for relapsed and refractory patients...
April 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28336303/rituximab-maintenance-improves-overall-survival-of-patients-with-follicular-lymphoma-individual-patient-data-meta-analysis
#2
Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H J van Oers, Catherine Fortpied, Michele Ghielmini, Ruth Pettengell, Mathias Witzens-Harig, Peter Dreger, Umberto Vitolo, Maria Gomes da Silva, Andrea Evangelista, Hailun Li, Laurence Freedman, Thomas M Habermann, Ofer Shpilberg
BACKGROUND: Randomised trials of rituximab maintenance (MR) for patients with follicular lymphoma support improved progression-free survival (PFS), but the effect on overall survival has been inconclusive. To evaluate the effect of MR on overall survival according to patient and disease characteristics, and to explore certain adverse events, we performed an individual patient data (IPD) meta-analysis. METHODS: All investigators of randomised controlled trials that compared MR therapy with observation or treatment only at relapse (no MR) for patients with follicular lymphoma were invited to participate in an IPD meta-analysis...
March 20, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28332735/non-hodgkin-lymphoma-in-south-east-asia-an-analysis-of-the-histopathology-clinical-features-and-survival-from-thailand
#3
Tanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn, Arnuparp Lekhakula, Jakrawadi Julamanee, Kanchana Chansung, Chittima Sirijerachai, Lalita Norasetthada, Weerasak Nawarawong, Archrob Khuhapinant, Noppadol Siritanaratanakul, Tontanai Numbenjapon, Kannadit Prayongratana, Suporn Chuncharunee, Pimjai Niparuck, Tawatchai Suwanban, Nongluk Kanitsap, Somchai Wongkhantee, Rutchanid Pornvipavee, Peerapon Wong, Nisa Makruasi, Pongsak Wannakrairot, Thamathorn Assanasen, Sanya Sukpanichnant, Paisarn Boonsakan, Wasana Kanoksil, Charin Ya-In, Kanita Kayasut, Winyu Mitranun, Naree Warnnissorn
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of Thai adult patients with NHL using large registries, especially those from Far East Asia (FEA). Using a web-based registry system, 13 major medical centers from the 4 geographic regions of Thailand prospectively collected, from 2007 to 2014, the diagnostic pathology, according to the World Health Organization classification, 2008, clinical features and survival of 4056 patients who were newly diagnosed with NHL...
March 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28331132/orbital-malt-lymphoma-after-autologous-stem-cell-transplantation-for-follicular-lymphoma-as-relapse-of-diffuse-large-b-cell-lymphoma
#4
Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii
We report a patient who developed orbital MALT lymphoma after autologous peripheral blood stem cell transplantation for follicular lymphoma as relapse of diffuse large B-cell lymphoma. A 54-year-old woman with systemic lymphadenopathy was diagnosed with diffuse large B-cell lymphoma by left supraclavicular lymph node biopsy, and underwent 6 courses of R-CHOP chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, leading to complete response. Five years later in the follow-up, an abdominal mass with abnormal uptake was found by whole-body 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography, and computed tomography-guided biopsy demonstrated follicular lymphoma...
2017: Journal of Clinical and Experimental Hematopathology: JCEH
https://www.readbyqxmd.com/read/28327933/newly-diagnosed-and-relapsed-follicular-lymphoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#5
M Dreyling, M Ghielmini, S Rule, G Salles, U Vitolo, M Ladetto
No abstract text is available yet for this article.
February 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28325864/idelalisib-is-effective-in-patients-with-high-risk-follicular-lymphoma-and-early-relapse-after-initial-chemoimmunotherapy
#6
Ajay K Gopal, Brad S Kahl, Christopher R Flowers, Peter Martin, Stephen M Ansell, Esteban Abella-Dominicis, Brian Koh, Wei Ye, Paul M Barr, Gilles A Salles, Jonathan W Friedberg
No abstract text is available yet for this article.
March 21, 2017: Blood
https://www.readbyqxmd.com/read/28324774/methylation-changes-of-sirt1-klf4-dapk1-and-spg20-in-b-lymphocytes-derived-from-follicular-and-diffuse-large-b-cell-lymphoma
#7
Raffaele Frazzi, Eleonora Zanetti, Mariaelena Pistoni, Ione Tamagnini, Riccardo Valli, Luca Braglia, Francesco Merli
Diffuse large-B cell lymphomas (DLBCL) and follicular lymphomas (FL) are the most represented subtypes among mature B-cell neoplasms and originate from malignant B lymphocytes. Methylation represents one of the major epigenetic mechanisms of gene regulation. Silent information regulator 1 (SIRT1) is a class III lysine-deacetylase playing several functions and considered to be a context-dependent tumor promoter. We present the quantitative methylation, gene expression and tissue distribution of SIRT1 and some key mediators related to lymphoma pathogenesis in B lymphocytes purified from biopsies of follicular hyperplasias, FL and DLBCL...
March 9, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28324270/obinutuzumab-a-review-in-rituximab-refractory-or-relapsed-follicular-lymphoma
#8
REVIEW
Sohita Dhillon
Obinutuzumab (Gazyva(®), Gazyvaro(®)) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the primary analysis of the large, phase III GADOLIN study, induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolonged progression-free survival (PFS) to a statistically significant extent relative to induction with bendamustine monotherapy in patients with indolent non-Hodgkin's lymphoma (iNHL)...
March 21, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28321641/transformed-follicular-lymphoma-tfl-consolidation-therapy-may-improve-survival
#9
E Elhassadi, R Flavin, P Browne, E Conneally, P Hayden, F Quinn, E Higgins, E Vandenberghe
PURPOSE: Retrospective study to evaluate the outcome of patients with transformed follicular lymphoma (tFL) treated with rituximab-containing chemotherapy and consolidation. PATIENTS AND METHODS: Patients diagnosed with tFL from 2003 to 2013 treated with consolidation therapy with last follow-up in December 2015 were identified from the institutional lymphoma database and included in this study. Data collected included age, gender, stage, interval to tFL diagnosis, R-IPI score, histological diagnosis and therapy...
March 21, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28314699/safety-and-tolerability-of-idelalisib-lenalidomide-and-rituximab-in-relapsed-and-refractory-lymphoma-the-alliance-for-clinical-trials-in-oncology-a051201-and-a051202-phase-1-trials
#10
Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, Nancy L Bartlett, Nina Wagner-Johnston, Steven I Park, Kristy L Richards, Amanda F Cashen, Anthony Jaslowski, Scott E Smith, Bruce D Cheson, Eric Hsi, John P Leonard
BACKGROUND: A new generation of biological and targeted agents might potentially replace traditional cytotoxic agents in lymphoma. Lenalidomide plus rituximab was felt to be a safe and promising backbone based on available data. Idelalisib is an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that has promising activity as a monotherapy in refractory indolent lymphomas. The primary objective of these two trials was to determine the maximum tolerated dose of lenalidomide in combination with rituximab and idelalisib in relapsed follicular and mantle cell lymphoma...
March 14, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28303495/genetic-landscape-and-classification-of-peripheral-t-cell-lymphomas
#11
REVIEW
Rosalind F Sandell, Rebecca L Boddicker, Andrew L Feldman
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification. RECENT FINDINGS: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. In anaplastic large cell lymphoma, these studies have revealed novel chromosomal rearrangements and mutations that have prognostic significance and may suggest new therapeutic approaches...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28300687/primary-multifocal-small-bowel-follicular-lymphoma-discovered-incidentally-on-diagnostic-endoscopy
#12
Zachary Junga, Amy Stratton, Jeffrey Laczek
This Image of the Month case is important for your readers and the field because it demonstrates a rare disease process of interest along with developments in the diagnosis and treatment of primary gastrointestinal follicular lymphomas.
March 11, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28295729/targeting-of-b-cell-receptor-signalling-in-b-cell-malignancies
#13
M Jerkeman, M Hallek, M Dreyling, C Thieblemont, E Kimby, L Staudt
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase Cβ. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma...
March 14, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28291388/lymphoma-remissions-caused-by-anti-cd19-chimeric-antigen-receptor-t-cells-are-associated-with-high-serum-interleukin-15-levels
#14
James N Kochenderfer, Robert P T Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John Rossi, Allen Xue, Stephanie L Goff, James C Yang, Richard M Sherry, Christopher A Klebanoff, Udai S Kammula, Marika Sherman, Arianne Perez, Constance M Yuan, Tatyana Feldman, Jonathan W Friedberg, Mark J Roschewski, Steven A Feldman, Lori McIntyre, Mary Ann Toomey, Steven A Rosenberg
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has been shown to enhance the antimalignancy activity of adoptively transferred T cells...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28288979/crebbp-loss-cooperates-with-bcl2-over-expression-to-promote-lymphoma-in-mice
#15
Idoia García-Ramírez, Saber Tadros, Inés González-Herrero, Alberto Martín-Lorenzo, Guillermo Rodríguez-Hernández, Dalia Moore, Lucía Ruiz-Roca, Oscar Blanco, Diego Alonso-López, Javier De Las Rivas, Keenan Hartert, Romain Duval, David Klinkebiel, Martin Bast, Julie Vose, Matthew Lunning, Kai Fu, Timothy Greiner, Fernando Rodrigues-Lima, Rafael Jiménez, Francisco Javier García Criado, María Begoña García Cenador, Paul Brindle, Carolina Vicente-Dueñas, Ash Alizadeh, Isidro Sánchez-García, Michael R Green
CREBBP is targeted by inactivating mutations in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Here, we provide evidence from transgenic mouse models that Crebbp deletion results in deficits in B-cell development and can cooperate with Bcl2 over-expression to promote B-cell lymphoma. Through transcriptional and epigenetic profiling of these B-cells we found that Crebbp inactivation was associated with broad transcriptional alterations, but no changes in the patterns of histone acetylation at the proximal regulatory regions of these genes...
March 13, 2017: Blood
https://www.readbyqxmd.com/read/28288712/the-role-of-stem-cell-transplantation-in-the-treatment-of-marginal-zone-lymphoma
#16
REVIEW
Avichai Shimoni
High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is standard therapy in relapsed/refractory aggressive lymphoma. The optimal therapy of relapsed/refractory disseminated marginal-zone lymphoma (MZL) has not been defined. Limited data on ASCT in this setting suggests outcomes are similar to what is expected in follicular lymphoma. International guidelines suggest that ASCT should be considered in follicular lymphoma in second or subsequent remission, in particular in high-risk disease, or following disease transformation...
March 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/28288708/transformation-of-marginal-zone-lymphoma-and-association-with-other-lymphomas
#17
REVIEW
Carla Casulo, Jonathan Friedberg
Marginal zone lymphomas (MZL) are a diverse group of indolent lymphoproliferative disorders that comprise three subtypes: nodal, splenic and mucosal associated marginal zone lymphomas (MALT). Histologic transformation (HT) to an aggressive lymphoma is a rare event that can occur in any subtype, and at lower frequency compared to other indolent non Hodgkin lymphomas (NHL) like follicular lymphoma. There are few data directly associated with risk and prognosis of transformation in MZL. However, recent advances in the understanding of molecular and genetic features of MALT have contributed to an evolving appreciation of HT in this disease...
March 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/28286923/maintenance-therapies-in-indolent-lymphomas-should-recent-data-change-the-standard-of-care
#18
REVIEW
Michael T Tees, Ian W Flinn
The overall benefit of maintenance therapy for patients with an indolent lymphoma continues to go unanswered. A myriad of variables contribute to the lack of clear clinical guidance. First, the disease course is slow and treatment may not be required for years, requiring a long follow-up to prospectively study. Second, due to the long lag time from study initiation to conclusion, many of the induction therapies used at the onset of the study may not be favored at present, providing a conclusion that cannot be reconciled with current clinical practice...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28285449/development-of-malignant-lymphoma-after-metal-on-metal-hip-replacement-a-case-report-and-review-of-the-literature
#19
C L McCarthy, Y Uchihara, M Vlychou, G Grammatopoulos, N A Athanasou
A number of previous studies have reported a potential risk of malignancy, particularly hematological malignancy, developing in patients receiving a metal-on-metal (MoM) hip replacement. We report a case of malignant lymphoma that arose in a patient who had an MoM hip arthroplasty complicated by development of a pseudotumour. The tumour was a B cell follicular lymphoma that involved lymph nodes and bone. Metal ions are known to have a genotoxic effect on lymphoid cells. Although epidemiological studies have not established that there is an increased risk of lymphoma associated with MoM implants, only a relatively short time period has elapsed since re-introduction of this type of implant and long-term follow-up of patients with MoM implants is indicated...
March 11, 2017: Skeletal Radiology
https://www.readbyqxmd.com/read/28284518/primary-lymphoma-of-the-female-genital-tract-an-analysis-of-697-cases
#20
Dimitrios Nasioudis, Polydoros N Kampaktsis, Melissa Frey, Steven S Witkin, Kevin Holcomb
OBJECTIVE: Primary lymphoma of the female genital tract (PLFGT) is a rare entity. The aim of this population-based study was to elucidate the clinico-pathological, demographic characteristics and survival of women with PLFGT. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results database was accessed and cases of PLFGT diagnosed between 1988 and 2012 were identified. Five-year overall (OS) and cancer-specific (CSS) survival rates were calculated with the Kaplan-Meier method...
March 9, 2017: Gynecologic Oncology
keyword
keyword
15642
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"